RE: Urocidin Now that was a very astute hypothesis Cat. The "Canadian" angle hasn't had much play.
Yet even an optimist might say that the BCG shortage will do for Urocidin what the XL Foods crisis did for Econiche... an "apparent" sum total of nothing.
My analysis says there is no value to P3a trial data. While its efficacy and safety profile was well above the FDA threshold for approval, it might as well not have occured. While we are at it, all the data collected to date, and yet to be collected in P3B until the last patient enrolled is through is "apparently" worthless as well.
If things were as dire as they appear to some, what would the the value of the MCC platform, maunfacturing centre in Pt. Claire and all the corresponding P3a and P3b data be worth on the market? We can even throw in post chemoo data as a bonus for eating the P3 a and b results to date. Maybe, but I doubt it, the whole bundle of garbage might have a positive value above negative 18 million the asset is currently assigned. If BNC were to do this, would it pay off the short and long term debt of the company?
There must be someone who can add a hypothetical monetary value to that asset? Seeing as we are trading as if banruptcy were imminent it might be a fun exercise.
It has to be worth more than the negative 15 - 20 cents/share that the market is currently assigning to it. Then again maybe the whole MCC shooting match is worth precisely the ($18,000,000) noose on the share price that the market says it is.